Recombinant human anti-RANKL antibody (Innovent Biologics)

重组全人源抗RANKL单克隆抗体（信达生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human anti-RANKL antibody (Innovent Biologics)
Drug Alias Name重组全人源抗RANKL单克隆抗体注射液（信达生物）IBI-307
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A